Accueil   Diary - News   All news iDD biotech enters worldwide agreement

iDD biotech enters worldwide agreement

iDD biotech has announced the signing of an agreement with Genmab, a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab will pay at iDD Biotech an upfront fee of EUR 2.5 million. Future payments range from a minimum of EUR 3.5 million to potentially EUR 101.5 million in development and sales milestones and single-digit royalties on commercialized products.

 

 

Read the press release